Geron (GERN) to Release Earnings on Wednesday

Geron (NASDAQ:GERN - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $49.88 million for the quarter.

Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Geron Trading Down 1.4 %

Shares of GERN stock opened at $1.38 on Wednesday. The firm's 50-day simple moving average is $1.59 and its 200-day simple moving average is $2.88. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. Geron has a 1-year low of $1.17 and a 1-year high of $5.34. The firm has a market cap of $878.94 million, a P/E ratio of -4.31 and a beta of 0.66.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on GERN. HC Wainwright reissued a "neutral" rating on shares of Geron in a research note on Wednesday, March 12th. B. Riley downgraded Geron from a "buy" rating to a "neutral" rating and lowered their price target for the company from $3.50 to $2.00 in a research report on Thursday, February 27th. Stifel Nicolaus cut their price objective on Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and set a $5.00 target price on shares of Geron in a report on Wednesday, March 12th. Finally, Scotiabank reduced their price target on shares of Geron from $6.00 to $4.00 and set a "sector outperform" rating on the stock in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $5.28.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.